Project Grant R01CA288824

Award Date 12/20/24
Completion Date 11/30/29
Dollars Obligated $592K
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90024, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $406,204 to DePaul University to develop and validate a novel model of visual-semantic processing for computer-aided diagnosis (CAD) systems. The goal is to create explainable and accurate CAD mechanisms that establish a common understanding of visually important patterns for radiologists. The research involves developing a semantic deep-learning neural network (SDNN) that...
This $700,611 Project Grant, awarded on March 11, 2025 by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, supports a practical randomized controlled trial (RCT) of artificial intelligence (AI) for melanoma diagnosis at Memorial Sloan Kettering Cancer Center (MSK) and Stanford University (SU). The goal is to determine the potential benefits and barriers to clinical adoption of AI-assisted dermoscopy, and to evaluate the impact on the...
The National Cancer Institute (NCI) awarded a 5-year, $1,192,358 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Cedars-Sinai Medical Center to assess, optimize, and deliver surgical feedback using artificial intelligence (AI) for benign urological robotic surgeries. The project aims to: 1) assess the current surgical feedback exchange between trainers and trainees during 500 urological surgery cases, 2) optimize human-delivered surgical feedback through statistical analysis and...
The National Cancer Institute (NCI) awarded a $570,634 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the University of Connecticut to develop a robust, multimodal, and longitudinal artificial intelligence (AI) system to enhance breast cancer screening. The overarching objective is to optimize and personalize breast cancer screening by advancing AI algorithms that can transform clinical decision-making. The key products/services to be delivered...
This federal Project Grant award of $680,433 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Regents of the University of California, San Francisco (UCSF) aims to apply advanced spatial proteogenomic and artificial intelligence technologies to improve prognostic estimation and understand the underlying biology driving pathology AI algorithms for prostate cancer. The key objectives are to: 1) explore the relationships between standard-of-care...
This $593,383 Project Grant, awarded by the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), is supporting the development of an AI-augmented, multimodal, label-free nonlinear optical microscopy system for rapid and precise diagnosis of thyroid cancer and lymph node metastasis. The primary awardee, The Methodist Hospital Research Institute, is collaborating with The Johns Hopkins University on this project. The proposed system aims to eliminate...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $762,258 to Cedars-Sinai Medical Center to conduct a cluster randomized controlled trial. The project aims to assess whether providing natural language processing (NLP)-based feedback with artificial intelligence (AI) summaries of key treatment tradeoffs to patients and physicians after prostate cancer consultations can improve patient decision-making and physician risk...
This $989,122 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to evaluate the performance of four commercial mammography-based artificial intelligence (AI) algorithms for breast cancer risk prediction in diverse U.S. screening populations. The project will assess the accuracy and equity of these AI risk models compared to traditional clinical risk factor-based models, using data from the Breast Cancer...
This Project Grant award of $677,998 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) will support research by The Medical College of Wisconsin, Inc. (MCW) to externally validate and integrate radio-pathomic models for delineating the true extent of glioma tumor infiltration. The research aims to develop non-invasive tools to aid in glioma treatment planning, monitoring treatment response, and guiding personalized therapies. Specifically, the...
This Project Grant award of $692,248, provided by the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to develop novel analytic methods for disease ruling (ruling-out or ruling-in) in cancer diagnosis to improve clinical decision-making. The project, led by Emory University, will focus on conceptual development of the analytic paradigm, as well as statistical and computational methods for formulating and estimating the performance of...

This $591,606 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, supports research to optimize human-computer interaction in pathology and understand the impact of computer-aided diagnosis (CAD) tools on pathologists' interpretive performance.

The project, led by the University of California, Los Angeles (UCLA), will randomize 250 pathologists to evaluate the effects of different types and timing of CAD cues on their diagnostic accuracy and interpretive behavior. The research leverages eye-tracking technology to provide insights into the perceptual and cognitive mechanisms underlying the impacts of CAD on the diagnostic process. Key sub-awardees include George Washington University, which will assist with survey development, study design, data collection and analysis, and the University of Washington, which will develop the CAD cues and lead statistical analysis. The goal is to inform best practices for deploying CAD tools into clinical practice to enhance their benefits and mitigate potential harms for patients.

Generated 8/5/25, 3:02 AM